阅读说明：本技术 寡糖化合物在治疗动脉型糖尿病患者的伤口中的用途 (Use of oligosaccharide compounds for treating wounds in patients with arterial diabetes ) 是由 S·博博 于 2018-05-16 设计创作，主要内容包括：本发明的主题是具有1-4个单糖单元的合成多硫酸化寡糖、其盐或其复合物在用于治疗动脉病患者的糖尿病足溃疡中的用途。(The subject of the present invention is the use of synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units, their salts or complexes thereof, for the treatment of diabetic foot ulcers in patients with arteriopathy.)

1. Use of a synthetic polysulfated oligosaccharide having 1-4 monosaccharide units, a salt or complex thereof, for the treatment of diabetic foot ulcers in patients with arteriopathy.

2. Use of an oligosaccharide according to claim 1 for activating healing of a diabetic foot ulcer in an arteriopathic patient.

3. Oligosaccharide according to claim 1 or 2, characterized in that the concentration is greater than or equal to 70mg/mL, preferably greater than or equal to 100mg/mL, more preferably 1000 mg/mL.

4. An oligosaccharide as claimed in any of the preceding claims, characterised in that it comprises 1-3 monosaccharide units, 1 or 2 monosaccharide units preferably selected from pentoses and hexoses, and salts and complexes of these compounds.

5. An oligosaccharide as claimed in any one of the preceding claims, characterised in that it is selected from:

-sucrose octasulfate potassium salt;

-sucrose octasulfate silver salt; and

-aluminum hydroxycomplex of sucrose octasulfate.

6. Oligosaccharide according to any one of the preceding claims, characterized in that it is sucrose octasulfate potassium salt.

7. Oligosaccharide according to any of the preceding claims, characterized in that it is used in the form of a composition such as a gelling agent, a solution, an emulsion, an ointment, granules or a capsule, so as to be able to be applied directly on a wound.

8. Use of a pharmaceutical composition comprising a synthetic polysulfated oligosaccharide having 1-4 monosaccharide units, a salt thereof or complex thereof, for the treatment of diabetic foot ulcers in patients suffering from arteriopathy.

9. Use of a dressing comprising a synthetic polysulfated oligosaccharide having 1-4 monosaccharide units, a salt thereof or complex thereof, in particular potassium sucrose octasulfate, for the treatment of diabetic foot ulcers in arteriopathic patients.

10. The dressing of claim 9 comprising fabric weft yarns coated with an elastomeric matrix comprising the synthetic polysulfated oligosaccharides.

Technical Field

The subject of the present invention is the use of synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units, of salts thereof or of complexes thereof, for treating diabetic foot ulcers in patients with arteriopathy, in particular for activating the healing of diabetic foot ulcers in patients with arteriopathy.

Background

Wound healing is a natural biological phenomenon, and mammalian tissues are able to repair local lesions through their characteristic repair and regeneration processes.

The speed and quality of wound healing depends on the overall condition of the affected organism, the etiology of the wound, the condition and location of the wound, and whether an infection has occurred, as well as genetic factors predisposed to a wound healing disorder.

The natural healing of wounds proceeds mainly according to three successive phases, each of which is characterized by a specific cellular activity which advances the repair process according to a precise temporal sequence: inflammatory stage, granulation stage (or proliferation stage) and maturation stage.

The first phase, the inflammatory phase, begins with the rupture of blood vessels, which triggers the formation of a blood clot (blood clot) composed mainly of fibrin and fibronectin, and which will form a temporary matrix. This matrix partially fills the lesion and enables the migration of recruited inflammatory cells within the damaged area to clean the wound. The platelets present also release factors (e.g., cytokines, growth factors) that can recruit healing cells, such as inflammatory cells (polynuclear neutrophils and macrophages), fibroblasts, and endothelial cells.

The second stage corresponds to the development of granulation tissue. First, the wound was observed to colonize by proliferating fibroblasts. Migration of vascular endothelial cells from healthy blood vessels will then enable the formation of new blood cells (neovascularization) or angiogenesis from the damaged tissue. This angiogenic step is the basis for initiating wound healing. In granulation tissue, fibroblasts are activated and differentiate into myofibroblasts with marked contractile properties, produced by actin microfilaments, thus contracting the wound.

The third phase of the repair process, the maturation phase, is accompanied by remodeling of granulation tissue. A portion of the extracellular matrix is digested by proteases, mainly Matrix Metalloproteinases (MMPs) and elastase, and gradual reorganization of the extracellular matrix is observed. Gradually, the predominant type III collagen in granulation tissue is replaced by type I collagen (the major matrix component of the dermis). At the end of the maturation phase, fibroblasts, myofibroblasts and vascular cells start to proliferate and/or their activity is reduced. The remaining cells then die by apoptosis. The inflammatory state gradually decreases with remodeling of the extracellular matrix and apoptosis of the remaining cells. This is the longest phase: after about one year, the scar is remodeled, it is no longer red, is no longer stiff, no longer causes pain and flattens.

However, despite the establishment of optimal physicochemical and biological conditions, certain types of wounds fail to heal properly, and abnormalities occur in all three critical stages of the process. In fact, the speed and quality of wound healing depends on both intrinsic and extrinsic factors. Thus, this repair process may be abnormally prolonged, depending on:

-the etiology of the wound;

-the condition thereof and the location thereof;

-the onset of infection caused by the presence of certain infectious agents (such as staphylococcus aureus or pseudomonas aeruginosa);

the presence of a once-ill condition (such as diabetes, immunodeficiency, venous insufficiency, etc.);

-an external environment; or

Genetic factors predisposed to wound healing disorders.

Chronic wounds, such as venous ulcers, bedsores or wounds characteristic of diabetic subjects, are found in these wounds. Chronic wounds are defined as non-healing after a six week interval from the appearance of the wound, regardless of the treatment method used. To treat such wounds, it may be important to accelerate the healing process.

Diabetic wounds are characterized by having their own proprietary very specific chronic wound types.

Diabetes is an increasingly common disease. According to recent estimates, about 2.85 million people worldwide have the disease, and this number reaches 4.39 million people by 2030. Diabetics face various complications related to their disease. Including increased incidence of cardiovascular flares (such as myocardial infarction), stroke, and microvascular complications such as retinal foci (which can lead to blindness) and renal disease (which can lead to renal failure). One of the most serious complications of diabetes is amputation. It is estimated that around the world, one person has had a lower limb amputated with Diabetes every 30 seconds, and 85% of these amputees have foot ulcers (International Diabetes Federation, IDF 2005). About 15% of diabetics develop foot ulcers during their lifetime.

The definition of Diabetic Foot Ulcer (DFU) is "full-thickness wound under the ankle, independent of duration for diabetic patients" (IDF, 2005). Indeed, the main reason for the inability of these diabetic wounds to heal is related to the deterioration of the bioavailability of glucose. This causes many physiological and metabolic changes, such as thickening of the skin, significant oxidative stress that may lead to neuropathy or arteriopathy. Thus, arteriopathy and neuropathy are two distinct risk factors for delayed wound healing in diabetic wounds, particularly in diabetic feet.

Diabetic foot ulcers are classified into different categories. Diabetic foot ulcers in neurological patients on the one hand, and diabetic foot ulcers in arterial patients who are clearly distinguishable from diabetic foot ulcers in neurological patients by the presence of ischemic lesions (in particular, characterized by a reduction in arterial blood supply to the organ). Thus, diabetic feet in neurological patients are often characterized by a warm, well-perfused foot and perceptible pulses of the foot arteries. In addition, patients with neurological disorders show a very marked, even complete loss of sensitivity at the level of their lesions. Ulcers are often located on the sole of the foot, beneath neglected callus that is subjected to strong plantar pressure. In contrast, diabetic feet of arteriopathy feel cold due to the inability to sense the pulse of the foot's arteries. Often, this is painful, as in this case the sensitivity of the patient is hardly or not impaired. However, this type of patient exhibits more or less pronounced lesions at the level of the wounded vessel, ranging from mere reduction of the blood supply to irreversible necrosis of the different vascular tissues that may lead to amputation at the level of the damaged area or even more. For this type of patient, the ulcerated portion is located at the level of the sole of the foot, but is also often located at the tip of the toes or in the region of the heel. Thus, the major clinical differences between diabetic foot ulcer forms require entirely different treatment regimens. For the treatment of neuropathic ulcers, it is desirable to remove as much necrotic tissue and calluses as possible in order to restart the wound healing process. In contrast, ischemic ulcers should not be cleared at risk of damaging the neo-angiogenesis stage before resuming the conventional wound healing process. Furthermore, the average rate of recovery is two to four times faster for patients with neuropathic ulcers than for patients with ischemic ulcers, ischemia severely hampers the healing process of the wound and increases the risk of infection, for example from the studies "comprehensive of characteristics and healing times by biological sources of biological assays: neuropathic, ischemic and neurological", Totsu RR et al, jdiases formulations, 2014Jul _ Aug; 28(4):528-35 ". Therefore, the currently proposed treatment of diabetic foot ulcers for neurological patients is not appropriate and cannot be transferred to arteriopathic patients. To date, no treatment (skin substitutes, growth factors, dressings or medical devices) has proven its efficacy for ischemic wounds.

Thus, there remains a need to find an effective treatment for diabetic foot ulcers in patients with arteriopathy where ischemia significantly complicates healing.

Disclosure of Invention

According to a first aspect, the present invention relates to the use of synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units, salts thereof or complexes thereof, for the treatment of diabetic foot ulcers in patients with arteriopathy.

According to a second aspect, the present invention also relates to the use of a pharmaceutical composition comprising a synthetic polysulfated oligosaccharide having 1-4 monosaccharide units, a salt thereof or a complex thereof, for the treatment of diabetic foot ulcers in patients with arteriopathy.

Patients with arterial disease

According to the present application, an "arteriopathy" is understood to be a diabetic patient who presents ischemia.

The Texas classification system described in the following publications clearly defines the distinction between neurological and arterial patients who exhibit ischemia: "A compositions of two diagnostic food customer classifications systems the Wagner and the University of Texas surround classification systems". Oyibo SO et al, Diabetes Care.2001Jan; 84-8 "and" A new classification of diagnostic Foot compatibility "a simple and effective textual tool", Dr AmitKumar C Jain et al, The Journal of diagnostic Foot compatibility, 2012; volume 4, Issue 1, No.1, Pages 1-5 ", which performs two-dimensional classification, as shown in the following table:

phases	Clinical observations
		A	No infection or ischemia
B	Infection without ischemia
		C	Ischemia without infection
D	Infection and ischemia

The patients with arteriopathy according to the present application belong to the classes IC and IIC, whereas the patients with neuropathy belong to the class IA.

First, ischemia may be confirmed by an ankle brachial pressure measurement of less than or equal to 0.9, preferably less than 0.8 and/or a big toe brachial pressure index measurement of less than or equal to 0.7.

Ischemia can be further confirmed by an ankle systolic pressure of 70mmHg or more and/or a big toe systolic pressure of 50mmHg or more.

Measuring one or more of these parameters makes it possible to identify the group of patients with arteriopathy according to the invention.

According to a particular embodiment, the arteriopathy according to the present application manifests itself by:

-ankle brachial pressure index greater than or equal to 0.9, preferably less than 0.8 or big toe brachial pressure index measurement less than or equal to 0.7,

and

-an ankle systolic pressure greater than or equal to 70mmHg and/or a big toe systolic pressure greater than or equal to 50 mmHg.

According to a preferred embodiment, the arteriopathy according to the application presents:

-ankle brachial pressure index ≤ 0.9, preferably less than 0.8, in combination with big toe systolic pressure ≥ 50mmHg, or, if big toe measurement (amputation) is not possible, ankle systolic pressure ≥ 70 mmHg;

-or ankle brachial pressure index >0.9, combined with big toe systolic pressure > 50mmHg and big toe brachial pressure index < 0.7.

Diabetic foot ulcer

The present invention provides the use of a synthetic polysulfated oligosaccharide having 1 to 4 monosaccharide units, a salt or complex thereof, for the treatment of diabetic foot ulcers in patients with arteriopathy.

As mentioned above, Diabetic Foot Ulcers (DFUs) are defined as "full-thickness wounds below the ankle of a diabetic, regardless of duration".

According to a particular embodiment, the diabetic foot ulcer treated within the scope of the present application has a size of less than 5cm²I.e. the wound is 5cm in area²Within the circle of (c).

According to another preferred embodiment, the diabetic foot ulcer treated within the scope of the present application is not recalcitrant, i.e. it forms less than 6 months ago.

Synthetic polysulfated with 1-4 monosaccharide unitsOligosaccharides

Oligosaccharides for use within the scope of the present invention are synthetic oligomers formed from 1 to 4 monosaccharide units, preferably 1 to 3 monosaccharide units, and more preferably 1 to 2 monosaccharide units, which are typically linked to each other by alpha or beta glycosidic linkages. In other words, it consists of a monosaccharide, disaccharide, trisaccharide or tetrasaccharide, preferably of a monosaccharide or disaccharide.

There are no particular restrictions with regard to the nature of the monosaccharide units of these polysaccharides. Preferably, they will consist of pentoses or hexoses. As examples of monosaccharides, mention may be made of glucose, galactose or mannose. As examples of disaccharides maltose, lactose, sucrose or trehalose may be mentioned. As an example of trisaccharide, melezitose may be mentioned. As an example of a tetrasaccharide, stachyose may be mentioned.

Preferably, the oligosaccharide is a disaccharide, more preferably sucrose.

According to the present application, "polysulfated oligosaccharides" are understood to be oligosaccharides in which at least two hydroxyl groups, and preferably all hydroxyl groups, of each monosaccharide have been substituted by a sulfate group.

Preferably, the polysulfated oligosaccharide used within the scope of the present application is sucrose octasulfate.

The polysulfated oligosaccharides used within the scope of the present invention may be present in the form of a salt or complex.

As examples of the salt, alkali metal salts such as sodium salt, calcium salt or potassium salt; a silver salt; or actually an amino acid salt.

As an example of the complex, a hydroxyaluminum complex may be mentioned.

Within the scope of the present invention, the following compounds are particularly preferred:

-sucrose octasulfate potassium salt;

-sucrose octasulfate silver salt; and

-a hydroxyaluminium complex of sucrose octasulfate, commonly known as sucralfate.

In particular, within the scope of the present invention, the polysulfated oligosaccharide used is preferably the potassium salt of sucrose octasulphate rather than the aluminium salt.

The polysulfated oligosaccharides used within the scope of the present invention may be present in the form of a micronized powder or in dissolved form.

An example of polysulfated oligosaccharides used within the scope of the present invention is the potassium salt of sucrose octasulfate (known by the acronym KSOS), produced as a product by the laboratory microorganisms URGO

And (4) selling the Start.

According to a particular embodiment, the synthetic polysulfated oligosaccharides according to the invention are used in a concentration greater than or equal to 70mg/mL, preferably greater than or equal to 100 mg/mL. According to a preferred embodiment, the synthetic polysulfated oligosaccharides according to the invention are used in a concentration of between 100mg/mL and 1000 mg/mL.

Composition comprising a metal oxide and a metal oxide

The invention also relates to the use of a pharmaceutical composition comprising the above synthetic polysulfated oligosaccharides for the treatment of diabetic foot ulcers in patients suffering from arteriopathy.

Other active substances

In general, the oligosaccharide compounds according to the invention can be used alone or as a mixture of two or more thereof, or indeed in combination with one (or more) other active substances.

Typically, the active substance is selected from the group consisting of antibacterial agents, antiseptics, analgesics, anti-inflammatories, wound healing promoting actives, depigmenting agents, antipruritics, uv filters, emollients, moisturizers, antioxidants and mixtures thereof.

Typically, the active substance is selected from:

antibacterial agents such as polymyxin B, penicillin (amoxicillin), clavulanic acid, tetracycline, minocycline, chlortetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (silver sulfadiazine), probiotics, silver salts;

preservatives, such as thimerosal, eosin, chlorhexidine, phenylmercuric borate, hydrogen peroxide, dactinous solution, triclosan, biguanides, hexamidine, thymol, Lugol, povidone iodine, mercury bromored, benzalkonium chloride and benzethonium chloride, ethanol, isopropanol;

analgesics such as paracetamol, codeine, dextropropoxyphene, tramadol, morphine and its derivatives, corticosteroids and their derivatives;

-anti-inflammatory agents such as glucocorticoids, non-steroidal anti-inflammatory agents, aspirin, ibuprofen, ketoprofen, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam, tenoxicam, naproxen, indomethacin, naproxcinod, nimesulide, celecoxib, etoxib, parecoxib, rofecoxib, valdecoxib, phenylbutazone, niflumic acid, mefenamic acid;

-active substances promoting wound healing, such as retinol; a vitamin A; a vitamin E; n-acetyl-hydroxyproline; centella asiatica extract; papain; a silicone; essential oils of thyme, melaleuca viridis (niaouli), rosemary and sage; hyaluronic acid; allantoin;

(gattefosse); vitamin C; TEGO Pep 4-17 (Evonik); toniskin (silab); collagene (expand); timecode (seppic); gatuline skinnopera (Gattefoss é); panthenol; PhytoCellTec Alp Rose (Mibelle Biochemistry); erasural (libragen), serilesine (lipotec); heterocycles of Talapetraka (Beyer); stoechiol (codif); macarose (sensor); dermaveil (Ichimaru Pharcos); phycosacatide AI (Codif);

depigmenting agents, such as Kojic Acid (Kojic Acid)

Quimasso (Sino lion), arbutin (Arbutin)

-a mixture of Quimasso (Sino lion), sodium palmitoylpropyl and Nymphaea alba extract (

-Seppic), undecylenoyl phenylalanine (-Seppic)；

-antipruritic agents: hydrocortisone, ionone, diphenhydramine, topical H1 antagonist antihistamines;

moisturizing actives such as xpermoist (lipotec), hyaluronic acid, urea, fatty acids, glycerol, waxes, exosine (unipex);

uv filters such as Parsol MCX, Parsol 1789;

emollients such as chamomile, bisabolol, xanthhalene, glycyrrhetinic acid (glycyrrhetic acid), tandaine (cpn), calimiskin (silab);

antioxidants, such as vitamin E.

According to a preferred embodiment, the oligosaccharide compound according to the invention can be used in combination with an antioxidant.

Galenic preparation

The synthetic polysulfated oligosaccharides used within the scope of the present invention can be applied topically, in particular in galenic formulations, such as gelling agents, solutions, emulsions, pastes, granules, capsules of various sizes ranging from nanometric or micrometric to millimetric, which enable their application to wounds. Alternatively, the compounds used within the scope of the present invention may be used in solutions for subcutaneous injection.

If they are used in mixtures of two or more, or indeed in combination with one or more other active substances, these compounds can be incorporated in the same galenical form or in separate galenical forms.

It is clear that the amount of synthetic polysulfated oligosaccharides according to the invention used in galenic formulations is adjusted according to the kinetics sought and the specific constraints relating to their properties, solubility, heat resistance, etc.

Dressing material

Preferably, the synthetic polysulfated oligosaccharides used within the scope of the invention or galenic preparations containing them are incorporated into dressings.

Synthetic polysulfated oligosaccharide compounds, particularly sucrose potassium octasulphate salts or galenic formulations, may be incorporated into any element of the dressing structure, provided that the compound may be in direct or indirect contact with the wound surface.

Preferably and in order to promote rapid action, such compounds (or galenic formulations containing them) are incorporated into a dressing layer or deposited on the surface of a dressing in contact with a wound.

Advantageously, the sucrose potassium octasulfate salt (or the galenic formulation containing it) can be deposited continuously or discontinuously on the surface intended to come into contact with the wound:

in liquid form, for example by spraying a solution or a suspension containing it;

or in solid form, for example by sieving a powder containing it.

For example, the layer or surface in contact with the wound may be made of an absorbent material (such as a polyurethane hydrophilic absorbent foam); textile materials (such as compresses); such as a nonwoven material; a film; a fiber tissue; optionally an absorbent adhesive material; and (3) optional adhesion interface structure composition.

Alternatively, for example, the layer or surface in contact with the wound may consist of textile weft yarns, preferably made of polyester as described in patent application WO 01/70285 or patent application WO2013/093298 onto which the elastomeric matrix comprising synthetic polysulfated oligosaccharides with 1-4 monosaccharide units, salts thereof or complexes thereof as described in patent application WO2008/149035 or application WO2014/009488, in particular sucrose potassium octasulfate salt, is to be covered or coated.

The invention therefore relates to the use of a dressing comprising textile weft yarns coated with an elastomeric matrix comprising synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units, their salts or complexes thereof, in particular the potassium salt of sucrose octasulfate, for the treatment of diabetic foot ulcers in patients with arteriopathy.

In general, the structure of the galenic formulation or dressing can be adjusted as desired to obtain a specific, rapid or delayed release profile of potassium sucrose octasulfate.

Obviously, the amount of sucrose potassium octasulfate salt used in the galenic formulation or dressing can be adjusted according to the kinetics sought and the specific constraints linked to its properties, solubility, heat resistance, etc.

According to the present application, dressing means all types of dressings used for wound treatment.

Typically, the dressing comprises at least one optional adhesive layer or matrix.

The synthetic polysulfated oligosaccharide compound according to the invention or the galenic formulation comprising it may be incorporated into any element of the dressing structure, for example the matrix.

Preferably, to promote rapid action, the compound (or galenic formulation containing it) may be incorporated into or deposited on the surface of the layer of the dressing in contact with the wound.

Such deposition techniques are well known to those skilled in the art. For example, it is described in patent application WO 2006/007814.

According to an alternative embodiment of the invention, the synthetic polysulfated oligosaccharide compound according to the invention can be incorporated into an absorbent dressing based on gelling fibres, for example the product sold by CONVATEC

Typically, when placing these dressings, the caregiver holds the latter in place using a belt, or covers the latter with a second element (such as a second absorbent dressing or compression band). It is therefore useful to keep the dressing secured to the wound so that the caregiver can release his hands to place these second elements. Generally, any type of adhesive may be used for this purpose.

In order not to damage healthy tissue or wound edges, especially when removing the dressing, an adhesive will be preferred which has the property of adhering to the skin and not to the wound.

As examples of such adhesives, mention may be made of adhesives based on silicon or polyurethane elastomers, such as silicone or polyurethane gelling agents, and hydrocolloid adhesives.

In particular, the hydrocolloid adhesive is composed of an elastomeric matrix based on one or more elastomers chosen from poly (styrene-olefin-styrene) sequential polymers, with one or more compounds chosen from plasticizers (such as mineral oils, tackifying resins) and, if desired, antioxidants, in which an amount, preferably a small amount, of a hydrocolloid (3% to 20% by weight), for example sodium carboxymethylcellulose, or a superabsorbent polymer such as BASF under the trade name of BASF, is incorporated

The product for sale.

According to a preferred embodiment, the synthetic polysulphide oligosaccharide compound or galenic preparation containing it used within the scope of the invention will be integrated in a dressing comprising a hydrocolloid adhesive, preferably the polysulphide oligosaccharide is incorporated in the adhesive in an amount of 1% to 15% by weight, more preferably 5% to 10% by weight, relative to the weight of the adhesive.

The formulation of such hydrophilic adhesives is well known to the person skilled in the art, for example those described in patent applications FR 2783412, FR 2392076 and FR 2495473.

It is particularly advantageous that the use of an adhesive web on the nonwoven reduces or prevents fine textile material fibres from coming into contact with the wound and sticking to the tissue, thereby triggering a painful sensation upon removal and even hindering the risk of the healing process of the wound.

According to a preferred alternative embodiment of the invention, the synthetic polysulfated oligosaccharide compound according to the invention is incorporated into such an adhesive in a concentration compatible with its solubility and its heat resistance.

Based on these criteria, the synthetic polysulfated oligosaccharide compound of the invention is preferably used in an amount of from 1 to 15% by weight, more preferably from 5 to 10% by weight, relative to the total weight of the binder.

If it is attempted to increase the absorbency of such a nonwoven dressing, it can be combined with other absorbent layers, preferably non-gelling absorbent layers, such as compresses in particular (such as in products)

Duo orAs used in Trio), absorbent hydrophilic foams (preferably hydrophilic polyurethane foams, having greater adsorption capacity than nonwovens such as productsUsed in (1)).

According to a preferred embodiment, the synthetic polysulfated oligosaccharide compound according to the invention is incorporated into a nonwoven dressing which is associated with other absorbent layers, and preferably a non-gelling absorbent layer (such as a dressing in particular).

According to another preferred embodiment, the synthetic polysulfated oligosaccharide compound according to the invention is incorporated into a nonwoven dressing in combination with other absorbent layers, and preferably a non-gelling absorbent layer (in particular such as an absorbent hydrophilic foam, preferably a hydrophilic polyurethane foam having a greater absorbent capacity than the nonwoven).

The nonwovens and foams may be obtained in connection with techniques well known to the person skilled in the art, for example by hot-rolling using hot-melt powders based on TPU/polycaprolactone polymers.

This technique is commonly used to bond nonwovens used in the medical market to one another.

Finally, the foam and the nonwoven (when the latter is used alone) may be covered with a substrate to protect the wound from the outside.

The substrate may be larger in size than the other layers and the adhesive is provided continuously or discontinuously on its surface in contact with the wound, thereby optimizing the fixation of the dressing during use of the dressing, particularly in cases where the wound is located on a non-planar body area.

Preferably, the substrate and its adhesive are fluid impermeable, but water vapour is very permeable, so that the exudate absorbed by the dressing can be optimally treated and impregnation problems prevented.

Such substrates are well known to those skilled in the art and consist, for example, of breathable and impermeable films such as polyurethane films, foams/films or nonwoven/film composites.

Additive agent

In addition to the active agent, the oligosaccharide compound according to the invention may be used in combination with one (or more) additive(s) conventionally used in the preparation of dressings. In particular, these additives may be selected from perfumes, preservatives, vitamins, glycerin, citric acid, and the like.

The activity of the synthetic polysulfated oligosaccharides according to the invention is demonstrated in the following non-limiting examples.

Detailed Description